Apr 17, 2008

Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines

Molecular Cancer Therapeutics
Joel GreshockTal Zaks

Abstract

A common aim of pharmacogenomic studies that use genome-wide assays on panels of cancers is the unbiased discovery of genomic alterations that are associated with clinical outcome and drug response. Previous studies of lapatinib, a selective dual-kinase inhibitor of epidermal growth factor receptor (EGFR) and HER2 tyrosine kinases, have shown predictable relationships between the activity of these target genes and response. Under the hypothesis that additional genes may play a role in drug sensitivity, a predictive model for lapatinib response was constructed from genome-wide DNA copy number data from 24 cancer cell lines. An optimal predictive model which consists of aberrations at nine distinct genetic loci, includes gains of HER2, EGFR, and loss of CDKN2A. This model achieved an area under the receiver operating characteristic curve of approximately 0.85 (80% confidence interval, 0.70-0.98; P < 0.01), and correctly classified the sensitivity status of 8 of 10 head and neck cancer cell lines. This study shows that biomarkers predictive for lapatinib sensitivity, including the previously described copy number gains of EGFR and HER2, can be discovered using novel genomic assays in an unbiased manner. Furthermore, these results ...Continue Reading

  • References
  • Citations9

References

  • We're still populating references for this paper, please check back later.

Mentioned in this Paper

ErbB-2 Receptor
Drug Response
Gene Expression Regulation, Neoplastic
Antineoplastic Agents
Gene Dosage
Genome
Cyclin-Dependent Kinase Inhibitor p16
Epidermal Growth Factor Receptor Activity
Neoplasms
Lapatinib ditosylate

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cancer Genomics

Cancer genomics employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research here.

Related Papers

The New England Journal of Medicine
Charles E GeyerDavid Cameron
Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Fred R HirschWilbur A Franklin
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
María J PajaresLuis M Montuenga
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Nancy U LinEric P Winer
© 2020 Meta ULC. All rights reserved